I noticed it seems to be a smooth transition based on the advance notice. Just from conference calls I didn't put much value on the CEO so I'm not that shaken by it but you would know better than me :-)
I actually thought people would get more excited about the ability to deliver enzymes orally. I don't know if the market doesn't buy it yet or I underestimated the value.
News 
Market Data 
Discover 
